GYRE THERAPEUTICS, INC. (GYRE) › Shareholders' EquityGYRE THERAPEUTICS, INC. (GYRE) — Shareholders' EquityAnnual figures by period end, from SEC filings.2008-12-31: $57.37M2009-12-31: $68.99M2010-12-31: $91.85M2011-12-31: $174.29M2012-12-31: -$93.34M2013-12-31: -$103.01M2014-12-31: -$109.35M2015-12-31: $31.43M2016-12-31: $16.07M2017-12-31: $30.77M2018-12-31: $119.94M2019-12-31: $68.34M2020-12-31: $76.07M2021-12-31: $41.09M2022-12-31: $42.52M2023-12-31: -$15.83M2024-12-31: $63.32M2025-12-31: $106.03M$106.03M2008-12-31Shareholders' Equity (USD)2025-12-31Period endedShareholders' EquityChange YoYSource filing2025-12-31$106.03M+67.5%2026-03-13Balance as of period end2024-12-31$63.32M—2026-03-13Balance as of period end2023-12-31-$15.83M-137.2%2025-03-17Balance as of period end2022-12-31$42.52M+3.5%2024-03-27Balance as of period end2021-12-31$41.09M-46.0%2023-03-30Balance as of period end2020-12-31$76.07M+11.3%2023-03-30Balance as of period end2019-12-31$68.34M-43.0%2022-03-31Balance as of period end2018-12-31$119.94M+289.8%2021-03-04Balance as of period end2017-12-31$30.77M+91.5%2020-02-20Balance as of period end2016-12-31$16.07M-48.9%2019-03-08Balance as of period end2015-12-31$31.43M—2018-03-19Balance as of period end2014-12-31-$109.35M—2017-03-08Balance as of period end2013-12-31-$103.01M—2016-03-09Balance as of period end2012-12-31-$93.34M-153.6%2016-03-09Balance as of period end2011-12-31$174.29M+89.8%2015-03-16Balance as of period end2010-12-31$91.85M+33.1%2014-03-14Balance as of period end2009-12-31$68.99M+20.2%2013-03-15Balance as of period end2008-12-31$57.37M—2012-03-06Balance as of period endOther metrics: RevenueCost of RevenueGross ProfitOperating IncomeNet IncomeEPS (Diluted)Total AssetsTotal LiabilitiesCash & EquivalentsOperating Cash FlowCapital ExpendituresShares OutstandingDividends Per ShareWeighted Average Diluted SharesEPS (Basic)